Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + ICE in Relapsed/Refractory PTCL
NCT03212937Phase 1Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Jul 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in peripheral T-cell lymphoma (PTCL), sponsored by National Cancer Centre Singapore. Primary endpoint: Dose Limiting Toxicity at 3 weeks. Started Jul 2016; status: completed.
02
Drugs
selinexor
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03212937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212937.